Replies to post #284595 on Amarin Corp Plc (AMRN)

[ilovetech]

Raf-Bingo!

[marjac]

Raf, see my Post #284452 directly addressing that concern as overblown. Patent cases would never settle and companies would never get sold if what you say, was the case.

[mrmainstreet]

Raf, we need a new poll that forces one answer. Will the Du ruling be reversed, affirmed, remanded, or will the parties settle? Let's see where people land when they must pick a single outcome, not probabilities.

[Biobillionair]

Really? Thanks Raf. And why would Amarin negotiate such idiotic terms? 2028 entry? That would be reckless of Amarin to not offer same time of entry but offer to supply H&R.... JMO. BB

[Ray]

I don't see this happening. The way the EPA market will be shaping up by 2029, we'll have Amarin, Hikma, Apotex, Teva & DR. A total of five players will not provide incentive for additional generics. If AMRN hopes to maintain its moat (assuming patent victory), it will have to redefine current formulation, discovery adjacent markets or buy out supply chain.

We're also losing time. With every passing month, the potential valuation of this firm will continue to diminish. JT and team need an execution plan NOW!